Pilon D, Brodeur J, Plaa G L
Département de Pharmacologie, Faculté de Médecine, Université de Montréal, Québec, Canada.
Toxicol Appl Pharmacol. 1988 Jun 30;94(2):183-90. doi: 10.1016/0041-008x(88)90260-8.
Potentiation of haloalkane hepatotoxicity by ketones and ketogenic agents is a well-known phenomenon. The importance of the CCl4 dosage in these combinations, however, has not been explored. Its influence was investigated in male Sprague-Dawley rats. Dose-effect curves for potentiation were generated using 1,3-butanediol, methyl n-butyl ketone or methyl isobutyl ketone as potentiation agents. Animals were orally treated with these compounds prior to a challenge of CCl4 (0 to 0.5 ml/kg, ip). Liver injury was assessed by monitoring plasma ALT activity and bilirubin concentrations after CCl4 treatment. The minimal effective dosage (MED) for each potentiator was used as the criterion of comparison for each combination. The MED values were determined from the plasma ALT data. Results showed that when the CCl4 dosage was increased from 0.01 to 0.10 ml/kg, the MED of each potentiator decreased 10-fold. For a given potentiator, the product of the CCl4 dosage (H, "hepatotoxicant") by the corresponding MED value (P, "potentiator") remained the same in this range of CCL4 dosages. The severity of the liver injury was similar. These findings suggest that a given level of liver injury induced by a ketone/haloalkane combination could be evaluated on the basis of the [P X H] product.
酮类和生酮剂增强卤代烷肝毒性是一个众所周知的现象。然而,在这些组合中四氯化碳剂量的重要性尚未得到探讨。在雄性斯普拉格-道利大鼠中研究了其影响。使用1,3-丁二醇、甲基正丁基酮或甲基异丁基酮作为增强剂生成增强作用的剂量-效应曲线。在给予四氯化碳(0至0.5毫升/千克,腹腔注射)挑战之前,对动物进行这些化合物的口服治疗。通过监测四氯化碳治疗后血浆谷丙转氨酶(ALT)活性和胆红素浓度来评估肝损伤。每种增强剂的最小有效剂量(MED)用作每种组合比较的标准。MED值由血浆ALT数据确定。结果表明,当四氯化碳剂量从0.01增加到0.10毫升/千克时,每种增强剂的MED降低了10倍。对于给定的增强剂,在该四氯化碳剂量范围内,四氯化碳剂量(H,“肝毒物”)与相应的MED值(P,“增强剂”)的乘积保持不变。肝损伤的严重程度相似。这些发现表明,由酮/卤代烷组合引起的给定水平的肝损伤可以基于[P×H]乘积来评估。